nodes	percent_of_prediction	percent_of_DWPC	metapath
Avanafil—PDE5A—Pentoxifylline—systemic scleroderma	0.747	0.964	CbGbCtD
Avanafil—PDE5A—pulmonary artery—systemic scleroderma	0.0226	0.386	CbGeAlD
Avanafil—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0157	0.0203	CbGbCtD
Avanafil—CYP3A4—Prednisone—systemic scleroderma	0.0126	0.0162	CbGbCtD
Avanafil—PDE5A—artery—systemic scleroderma	0.00838	0.143	CbGeAlD
Avanafil—PDE5A—endothelium—systemic scleroderma	0.00708	0.121	CbGeAlD
Avanafil—PDE5A—blood vessel—systemic scleroderma	0.00653	0.112	CbGeAlD
Avanafil—PDE5A—connective tissue—systemic scleroderma	0.00335	0.0572	CbGeAlD
Avanafil—PDE5A—smooth muscle tissue—systemic scleroderma	0.00306	0.0523	CbGeAlD
Avanafil—PDE5A—digestive system—systemic scleroderma	0.00242	0.0413	CbGeAlD
Avanafil—PDE5A—tendon—systemic scleroderma	0.0023	0.0393	CbGeAlD
Avanafil—PDE5A—lung—systemic scleroderma	0.00202	0.0345	CbGeAlD
Avanafil—CYP3A4—digestive system—systemic scleroderma	0.000753	0.0129	CbGeAlD
Avanafil—Infection—Azathioprine—systemic scleroderma	0.000272	0.00164	CcSEcCtD
Avanafil—Vertigo—Mycophenolic acid—systemic scleroderma	0.000272	0.00164	CcSEcCtD
Avanafil—Urinary tract disorder—Mycophenolate mofetil—systemic scleroderma	0.000271	0.00163	CcSEcCtD
Avanafil—Fatigue—Captopril—systemic scleroderma	0.000271	0.00163	CcSEcCtD
Avanafil—Oedema peripheral—Mycophenolate mofetil—systemic scleroderma	0.00027	0.00163	CcSEcCtD
Avanafil—Arthralgia—Leflunomide—systemic scleroderma	0.00027	0.00163	CcSEcCtD
Avanafil—Chest pain—Leflunomide—systemic scleroderma	0.00027	0.00163	CcSEcCtD
Avanafil—Myalgia—Leflunomide—systemic scleroderma	0.00027	0.00163	CcSEcCtD
Avanafil—Connective tissue disorder—Mycophenolate mofetil—systemic scleroderma	0.00027	0.00162	CcSEcCtD
Avanafil—Urethral disorder—Mycophenolate mofetil—systemic scleroderma	0.000269	0.00162	CcSEcCtD
Avanafil—Constipation—Captopril—systemic scleroderma	0.000269	0.00162	CcSEcCtD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.000268	0.00162	CcSEcCtD
Avanafil—Palpitations—Mycophenolic acid—systemic scleroderma	0.000267	0.00161	CcSEcCtD
Avanafil—Skin disorder—Azathioprine—systemic scleroderma	0.000266	0.0016	CcSEcCtD
Avanafil—Dry mouth—Leflunomide—systemic scleroderma	0.000264	0.00159	CcSEcCtD
Avanafil—Cough—Mycophenolic acid—systemic scleroderma	0.000264	0.00159	CcSEcCtD
Avanafil—Back pain—Lisinopril—systemic scleroderma	0.000264	0.00159	CcSEcCtD
Avanafil—Vomiting—Pentoxifylline—systemic scleroderma	0.000264	0.00159	CcSEcCtD
Avanafil—Muscle spasms—Lisinopril—systemic scleroderma	0.000262	0.00158	CcSEcCtD
Avanafil—Rash—Pentoxifylline—systemic scleroderma	0.000261	0.00157	CcSEcCtD
Avanafil—Hypertension—Mycophenolic acid—systemic scleroderma	0.000261	0.00157	CcSEcCtD
Avanafil—Dermatitis—Pentoxifylline—systemic scleroderma	0.000261	0.00157	CcSEcCtD
Avanafil—Headache—Pentoxifylline—systemic scleroderma	0.00026	0.00156	CcSEcCtD
Avanafil—Diabetes mellitus—Methotrexate—systemic scleroderma	0.000258	0.00156	CcSEcCtD
Avanafil—Myalgia—Mycophenolic acid—systemic scleroderma	0.000258	0.00155	CcSEcCtD
Avanafil—Chest pain—Mycophenolic acid—systemic scleroderma	0.000258	0.00155	CcSEcCtD
Avanafil—Arthralgia—Mycophenolic acid—systemic scleroderma	0.000258	0.00155	CcSEcCtD
Avanafil—Infection—Leflunomide—systemic scleroderma	0.000257	0.00155	CcSEcCtD
Avanafil—Vision blurred—Lisinopril—systemic scleroderma	0.000257	0.00155	CcSEcCtD
Avanafil—Asthenia—Mometasone—systemic scleroderma	0.000257	0.00155	CcSEcCtD
Avanafil—Eye disorder—Mycophenolate mofetil—systemic scleroderma	0.000256	0.00155	CcSEcCtD
Avanafil—Hypotension—Azathioprine—systemic scleroderma	0.000256	0.00154	CcSEcCtD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.000256	0.00154	CcSEcCtD
Avanafil—Cardiac disorder—Mycophenolate mofetil—systemic scleroderma	0.000255	0.00153	CcSEcCtD
Avanafil—Nervous system disorder—Leflunomide—systemic scleroderma	0.000254	0.00153	CcSEcCtD
Avanafil—Pruritus—Mometasone—systemic scleroderma	0.000253	0.00152	CcSEcCtD
Avanafil—Tachycardia—Leflunomide—systemic scleroderma	0.000253	0.00152	CcSEcCtD
Avanafil—Dry mouth—Mycophenolic acid—systemic scleroderma	0.000252	0.00152	CcSEcCtD
Avanafil—Skin disorder—Leflunomide—systemic scleroderma	0.000252	0.00152	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	0.00025	0.00151	CcSEcCtD
Avanafil—Angiopathy—Mycophenolate mofetil—systemic scleroderma	0.000249	0.0015	CcSEcCtD
Avanafil—Body temperature increased—Captopril—systemic scleroderma	0.000248	0.0015	CcSEcCtD
Avanafil—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000247	0.00149	CcSEcCtD
Avanafil—Nausea—Pentoxifylline—systemic scleroderma	0.000246	0.00148	CcSEcCtD
Avanafil—Infection—Mycophenolic acid—systemic scleroderma	0.000245	0.00148	CcSEcCtD
Avanafil—Vertigo—Lisinopril—systemic scleroderma	0.000245	0.00148	CcSEcCtD
Avanafil—Diarrhoea—Mometasone—systemic scleroderma	0.000245	0.00147	CcSEcCtD
Avanafil—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.000242	0.00146	CcSEcCtD
Avanafil—Hypotension—Leflunomide—systemic scleroderma	0.000242	0.00146	CcSEcCtD
Avanafil—Tachycardia—Mycophenolic acid—systemic scleroderma	0.000241	0.00145	CcSEcCtD
Avanafil—Palpitations—Lisinopril—systemic scleroderma	0.000241	0.00145	CcSEcCtD
Avanafil—Mental disorder—Mycophenolate mofetil—systemic scleroderma	0.00024	0.00145	CcSEcCtD
Avanafil—Skin disorder—Mycophenolic acid—systemic scleroderma	0.00024	0.00145	CcSEcCtD
Avanafil—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.000239	0.00144	CcSEcCtD
Avanafil—Cough—Lisinopril—systemic scleroderma	0.000238	0.00143	CcSEcCtD
Avanafil—Alanine aminotransferase increased—Prednisone—systemic scleroderma	0.000237	0.00143	CcSEcCtD
Avanafil—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000237	0.00143	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.000236	0.00142	CcSEcCtD
Avanafil—Insomnia—Leflunomide—systemic scleroderma	0.000234	0.00141	CcSEcCtD
Avanafil—Arthralgia—Lisinopril—systemic scleroderma	0.000232	0.0014	CcSEcCtD
Avanafil—Myalgia—Lisinopril—systemic scleroderma	0.000232	0.0014	CcSEcCtD
Avanafil—Chest pain—Lisinopril—systemic scleroderma	0.000232	0.0014	CcSEcCtD
Avanafil—Back pain—Mycophenolate mofetil—systemic scleroderma	0.000231	0.00139	CcSEcCtD
Avanafil—Hypotension—Mycophenolic acid—systemic scleroderma	0.000231	0.00139	CcSEcCtD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000231	0.00139	CcSEcCtD
Avanafil—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.00023	0.00138	CcSEcCtD
Avanafil—Dyspepsia—Leflunomide—systemic scleroderma	0.000228	0.00137	CcSEcCtD
Avanafil—Vomiting—Mometasone—systemic scleroderma	0.000227	0.00137	CcSEcCtD
Avanafil—Dry mouth—Lisinopril—systemic scleroderma	0.000227	0.00137	CcSEcCtD
Avanafil—Rash—Mometasone—systemic scleroderma	0.000226	0.00136	CcSEcCtD
Avanafil—Asthenia—Captopril—systemic scleroderma	0.000225	0.00136	CcSEcCtD
Avanafil—Dermatitis—Mometasone—systemic scleroderma	0.000225	0.00136	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000225	0.00136	CcSEcCtD
Avanafil—Headache—Mometasone—systemic scleroderma	0.000224	0.00135	CcSEcCtD
Avanafil—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000224	0.00135	CcSEcCtD
Avanafil—Insomnia—Mycophenolic acid—systemic scleroderma	0.000223	0.00135	CcSEcCtD
Avanafil—Fatigue—Leflunomide—systemic scleroderma	0.000223	0.00135	CcSEcCtD
Avanafil—Pruritus—Captopril—systemic scleroderma	0.000222	0.00134	CcSEcCtD
Avanafil—Constipation—Leflunomide—systemic scleroderma	0.000221	0.00133	CcSEcCtD
Avanafil—Infection—Lisinopril—systemic scleroderma	0.000221	0.00133	CcSEcCtD
Avanafil—Somnolence—Mycophenolic acid—systemic scleroderma	0.00022	0.00132	CcSEcCtD
Avanafil—Agitation—Mycophenolate mofetil—systemic scleroderma	0.00022	0.00132	CcSEcCtD
Avanafil—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000217	0.00131	CcSEcCtD
Avanafil—Tachycardia—Lisinopril—systemic scleroderma	0.000217	0.00131	CcSEcCtD
Avanafil—Body temperature increased—Azathioprine—systemic scleroderma	0.000217	0.00131	CcSEcCtD
Avanafil—Skin disorder—Lisinopril—systemic scleroderma	0.000216	0.0013	CcSEcCtD
Avanafil—Diarrhoea—Captopril—systemic scleroderma	0.000215	0.0013	CcSEcCtD
Avanafil—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.000215	0.00129	CcSEcCtD
Avanafil—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000213	0.00128	CcSEcCtD
Avanafil—Fatigue—Mycophenolic acid—systemic scleroderma	0.000213	0.00128	CcSEcCtD
Avanafil—Nausea—Mometasone—systemic scleroderma	0.000212	0.00128	CcSEcCtD
Avanafil—Weight increased—Prednisone—systemic scleroderma	0.000211	0.00127	CcSEcCtD
Avanafil—Constipation—Mycophenolic acid—systemic scleroderma	0.000211	0.00127	CcSEcCtD
Avanafil—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000211	0.00127	CcSEcCtD
Avanafil—Cough—Mycophenolate mofetil—systemic scleroderma	0.000208	0.00126	CcSEcCtD
Avanafil—Hypotension—Lisinopril—systemic scleroderma	0.000208	0.00125	CcSEcCtD
Avanafil—Dizziness—Captopril—systemic scleroderma	0.000208	0.00125	CcSEcCtD
Avanafil—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000206	0.00124	CcSEcCtD
Avanafil—Body temperature increased—Leflunomide—systemic scleroderma	0.000205	0.00123	CcSEcCtD
Avanafil—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000203	0.00123	CcSEcCtD
Avanafil—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000203	0.00123	CcSEcCtD
Avanafil—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000203	0.00123	CcSEcCtD
Avanafil—Breast disorder—Methotrexate—systemic scleroderma	0.000203	0.00122	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000203	0.00122	CcSEcCtD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000202	0.00122	CcSEcCtD
Avanafil—Insomnia—Lisinopril—systemic scleroderma	0.000201	0.00121	CcSEcCtD
Avanafil—Vomiting—Captopril—systemic scleroderma	0.0002	0.0012	CcSEcCtD
Avanafil—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000199	0.0012	CcSEcCtD
Avanafil—Rash—Captopril—systemic scleroderma	0.000198	0.00119	CcSEcCtD
Avanafil—Dermatitis—Captopril—systemic scleroderma	0.000198	0.00119	CcSEcCtD
Avanafil—Somnolence—Lisinopril—systemic scleroderma	0.000198	0.00119	CcSEcCtD
Avanafil—Headache—Captopril—systemic scleroderma	0.000197	0.00119	CcSEcCtD
Avanafil—Dyspepsia—Lisinopril—systemic scleroderma	0.000196	0.00118	CcSEcCtD
Avanafil—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000195	0.00118	CcSEcCtD
Avanafil—Infection—Mycophenolate mofetil—systemic scleroderma	0.000194	0.00117	CcSEcCtD
Avanafil—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000192	0.00116	CcSEcCtD
Avanafil—Fatigue—Lisinopril—systemic scleroderma	0.000192	0.00116	CcSEcCtD
Avanafil—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000191	0.00115	CcSEcCtD
Avanafil—Constipation—Lisinopril—systemic scleroderma	0.00019	0.00115	CcSEcCtD
Avanafil—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.00019	0.00115	CcSEcCtD
Avanafil—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000189	0.00114	CcSEcCtD
Avanafil—Diarrhoea—Azathioprine—systemic scleroderma	0.000188	0.00113	CcSEcCtD
Avanafil—Nausea—Captopril—systemic scleroderma	0.000187	0.00112	CcSEcCtD
Avanafil—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000186	0.00112	CcSEcCtD
Avanafil—Asthenia—Leflunomide—systemic scleroderma	0.000186	0.00112	CcSEcCtD
Avanafil—Pruritus—Leflunomide—systemic scleroderma	0.000183	0.0011	CcSEcCtD
Avanafil—Connective tissue disorder—Prednisone—systemic scleroderma	0.000183	0.0011	CcSEcCtD
Avanafil—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000182	0.0011	CcSEcCtD
Avanafil—Dizziness—Azathioprine—systemic scleroderma	0.000181	0.00109	CcSEcCtD
Avanafil—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.00018	0.00109	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000178	0.00107	CcSEcCtD
Avanafil—Asthenia—Mycophenolic acid—systemic scleroderma	0.000177	0.00107	CcSEcCtD
Avanafil—Diarrhoea—Leflunomide—systemic scleroderma	0.000177	0.00107	CcSEcCtD
Avanafil—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000176	0.00106	CcSEcCtD
Avanafil—Body temperature increased—Lisinopril—systemic scleroderma	0.000176	0.00106	CcSEcCtD
Avanafil—Pruritus—Mycophenolic acid—systemic scleroderma	0.000175	0.00105	CcSEcCtD
Avanafil—Vomiting—Azathioprine—systemic scleroderma	0.000174	0.00105	CcSEcCtD
Avanafil—Eye disorder—Prednisone—systemic scleroderma	0.000174	0.00105	CcSEcCtD
Avanafil—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000173	0.00104	CcSEcCtD
Avanafil—Infestation—Methotrexate—systemic scleroderma	0.000173	0.00104	CcSEcCtD
Avanafil—Infestation NOS—Methotrexate—systemic scleroderma	0.000173	0.00104	CcSEcCtD
Avanafil—Rash—Azathioprine—systemic scleroderma	0.000173	0.00104	CcSEcCtD
Avanafil—Dermatitis—Azathioprine—systemic scleroderma	0.000173	0.00104	CcSEcCtD
Avanafil—Flushing—Prednisone—systemic scleroderma	0.000173	0.00104	CcSEcCtD
Avanafil—Headache—Azathioprine—systemic scleroderma	0.000172	0.00103	CcSEcCtD
Avanafil—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000172	0.00103	CcSEcCtD
Avanafil—Dizziness—Leflunomide—systemic scleroderma	0.000171	0.00103	CcSEcCtD
Avanafil—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000169	0.00102	CcSEcCtD
Avanafil—Angiopathy—Prednisone—systemic scleroderma	0.000169	0.00102	CcSEcCtD
Avanafil—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000168	0.00101	CcSEcCtD
Avanafil—Immune system disorder—Prednisone—systemic scleroderma	0.000168	0.00101	CcSEcCtD
Avanafil—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000167	0.001	CcSEcCtD
Avanafil—Haematuria—Methotrexate—systemic scleroderma	0.000165	0.000995	CcSEcCtD
Avanafil—Vomiting—Leflunomide—systemic scleroderma	0.000165	0.000992	CcSEcCtD
Avanafil—Dizziness—Mycophenolic acid—systemic scleroderma	0.000163	0.000984	CcSEcCtD
Avanafil—Epistaxis—Methotrexate—systemic scleroderma	0.000163	0.000984	CcSEcCtD
Avanafil—Rash—Leflunomide—systemic scleroderma	0.000163	0.000984	CcSEcCtD
Avanafil—Dermatitis—Leflunomide—systemic scleroderma	0.000163	0.000983	CcSEcCtD
Avanafil—Mental disorder—Prednisone—systemic scleroderma	0.000163	0.000982	CcSEcCtD
Avanafil—Nausea—Azathioprine—systemic scleroderma	0.000163	0.000981	CcSEcCtD
Avanafil—Headache—Leflunomide—systemic scleroderma	0.000162	0.000977	CcSEcCtD
Avanafil—Malnutrition—Prednisone—systemic scleroderma	0.000162	0.000976	CcSEcCtD
Avanafil—Asthenia—Lisinopril—systemic scleroderma	0.00016	0.000962	CcSEcCtD
Avanafil—Pruritus—Lisinopril—systemic scleroderma	0.000157	0.000948	CcSEcCtD
Avanafil—Vomiting—Mycophenolic acid—systemic scleroderma	0.000157	0.000946	CcSEcCtD
Avanafil—Rash—Mycophenolic acid—systemic scleroderma	0.000156	0.000938	CcSEcCtD
Avanafil—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000156	0.000938	CcSEcCtD
Avanafil—Headache—Mycophenolic acid—systemic scleroderma	0.000155	0.000932	CcSEcCtD
Avanafil—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000154	0.000929	CcSEcCtD
Avanafil—Nausea—Leflunomide—systemic scleroderma	0.000154	0.000927	CcSEcCtD
Avanafil—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000154	0.000925	CcSEcCtD
Avanafil—Vision blurred—Prednisone—systemic scleroderma	0.000153	0.000919	CcSEcCtD
Avanafil—Urethral disorder—Methotrexate—systemic scleroderma	0.000152	0.000918	CcSEcCtD
Avanafil—Diarrhoea—Lisinopril—systemic scleroderma	0.000152	0.000917	CcSEcCtD
Avanafil—Agitation—Prednisone—systemic scleroderma	0.000149	0.000897	CcSEcCtD
Avanafil—Dizziness—Lisinopril—systemic scleroderma	0.000147	0.000886	CcSEcCtD
Avanafil—Nausea—Mycophenolic acid—systemic scleroderma	0.000147	0.000884	CcSEcCtD
Avanafil—Vertigo—Prednisone—systemic scleroderma	0.000145	0.000876	CcSEcCtD
Avanafil—Eye disorder—Methotrexate—systemic scleroderma	0.000145	0.000875	CcSEcCtD
Avanafil—Cardiac disorder—Methotrexate—systemic scleroderma	0.000144	0.000869	CcSEcCtD
Avanafil—Vomiting—Lisinopril—systemic scleroderma	0.000141	0.000852	CcSEcCtD
Avanafil—Angiopathy—Methotrexate—systemic scleroderma	0.000141	0.00085	CcSEcCtD
Avanafil—Immune system disorder—Methotrexate—systemic scleroderma	0.00014	0.000846	CcSEcCtD
Avanafil—Rash—Lisinopril—systemic scleroderma	0.00014	0.000845	CcSEcCtD
Avanafil—Dermatitis—Lisinopril—systemic scleroderma	0.00014	0.000844	CcSEcCtD
Avanafil—Mediastinal disorder—Methotrexate—systemic scleroderma	0.00014	0.000844	CcSEcCtD
Avanafil—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.00014	0.000843	CcSEcCtD
Avanafil—Hypertension—Prednisone—systemic scleroderma	0.00014	0.000842	CcSEcCtD
Avanafil—Headache—Lisinopril—systemic scleroderma	0.000139	0.00084	CcSEcCtD
Avanafil—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000138	0.000831	CcSEcCtD
Avanafil—Arthralgia—Prednisone—systemic scleroderma	0.000138	0.000831	CcSEcCtD
Avanafil—Myalgia—Prednisone—systemic scleroderma	0.000138	0.000831	CcSEcCtD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000137	0.000825	CcSEcCtD
Avanafil—Mental disorder—Methotrexate—systemic scleroderma	0.000136	0.000821	CcSEcCtD
Avanafil—Malnutrition—Methotrexate—systemic scleroderma	0.000135	0.000815	CcSEcCtD
Avanafil—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000133	0.000804	CcSEcCtD
Avanafil—Nausea—Lisinopril—systemic scleroderma	0.000132	0.000796	CcSEcCtD
Avanafil—Infection—Prednisone—systemic scleroderma	0.000131	0.000791	CcSEcCtD
Avanafil—Back pain—Methotrexate—systemic scleroderma	0.000131	0.000789	CcSEcCtD
Avanafil—Nervous system disorder—Prednisone—systemic scleroderma	0.00013	0.000781	CcSEcCtD
Avanafil—Tachycardia—Prednisone—systemic scleroderma	0.000129	0.000777	CcSEcCtD
Avanafil—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000129	0.000777	CcSEcCtD
Avanafil—Skin disorder—Prednisone—systemic scleroderma	0.000128	0.000773	CcSEcCtD
Avanafil—Vision blurred—Methotrexate—systemic scleroderma	0.000128	0.000768	CcSEcCtD
Avanafil—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000124	0.000747	CcSEcCtD
Avanafil—Rash—Mycophenolate mofetil—systemic scleroderma	0.000123	0.000741	CcSEcCtD
Avanafil—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000123	0.00074	CcSEcCtD
Avanafil—Headache—Mycophenolate mofetil—systemic scleroderma	0.000122	0.000736	CcSEcCtD
Avanafil—Vertigo—Methotrexate—systemic scleroderma	0.000122	0.000732	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.00012	0.000725	CcSEcCtD
Avanafil—Insomnia—Prednisone—systemic scleroderma	0.00012	0.00072	CcSEcCtD
Avanafil—Cough—Methotrexate—systemic scleroderma	0.000118	0.000711	CcSEcCtD
Avanafil—Dyspepsia—Prednisone—systemic scleroderma	0.000116	0.000701	CcSEcCtD
Avanafil—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000116	0.000698	CcSEcCtD
Avanafil—Chest pain—Methotrexate—systemic scleroderma	0.000115	0.000694	CcSEcCtD
Avanafil—Myalgia—Methotrexate—systemic scleroderma	0.000115	0.000694	CcSEcCtD
Avanafil—Arthralgia—Methotrexate—systemic scleroderma	0.000115	0.000694	CcSEcCtD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000114	0.000689	CcSEcCtD
Avanafil—Fatigue—Prednisone—systemic scleroderma	0.000114	0.000686	CcSEcCtD
Avanafil—Constipation—Prednisone—systemic scleroderma	0.000113	0.000681	CcSEcCtD
Avanafil—Infection—Methotrexate—systemic scleroderma	0.00011	0.000661	CcSEcCtD
Avanafil—Nervous system disorder—Methotrexate—systemic scleroderma	0.000108	0.000653	CcSEcCtD
Avanafil—Skin disorder—Methotrexate—systemic scleroderma	0.000107	0.000646	CcSEcCtD
Avanafil—Body temperature increased—Prednisone—systemic scleroderma	0.000104	0.000629	CcSEcCtD
Avanafil—Hypotension—Methotrexate—systemic scleroderma	0.000103	0.000622	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000101	0.000606	CcSEcCtD
Avanafil—Insomnia—Methotrexate—systemic scleroderma	9.99e-05	0.000602	CcSEcCtD
Avanafil—Somnolence—Methotrexate—systemic scleroderma	9.82e-05	0.000592	CcSEcCtD
Avanafil—Dyspepsia—Methotrexate—systemic scleroderma	9.72e-05	0.000586	CcSEcCtD
Avanafil—Gastrointestinal disorder—Methotrexate—systemic scleroderma	9.53e-05	0.000574	CcSEcCtD
Avanafil—Fatigue—Methotrexate—systemic scleroderma	9.52e-05	0.000574	CcSEcCtD
Avanafil—Asthenia—Prednisone—systemic scleroderma	9.48e-05	0.000571	CcSEcCtD
Avanafil—Pruritus—Prednisone—systemic scleroderma	9.35e-05	0.000563	CcSEcCtD
Avanafil—Diarrhoea—Prednisone—systemic scleroderma	9.04e-05	0.000545	CcSEcCtD
Avanafil—Dizziness—Prednisone—systemic scleroderma	8.74e-05	0.000526	CcSEcCtD
Avanafil—Body temperature increased—Methotrexate—systemic scleroderma	8.73e-05	0.000526	CcSEcCtD
Avanafil—Vomiting—Prednisone—systemic scleroderma	8.4e-05	0.000506	CcSEcCtD
Avanafil—Rash—Prednisone—systemic scleroderma	8.33e-05	0.000502	CcSEcCtD
Avanafil—Dermatitis—Prednisone—systemic scleroderma	8.32e-05	0.000502	CcSEcCtD
Avanafil—Headache—Prednisone—systemic scleroderma	8.28e-05	0.000499	CcSEcCtD
Avanafil—Asthenia—Methotrexate—systemic scleroderma	7.92e-05	0.000477	CcSEcCtD
Avanafil—Nausea—Prednisone—systemic scleroderma	7.85e-05	0.000473	CcSEcCtD
Avanafil—Pruritus—Methotrexate—systemic scleroderma	7.81e-05	0.000471	CcSEcCtD
Avanafil—Diarrhoea—Methotrexate—systemic scleroderma	7.56e-05	0.000455	CcSEcCtD
Avanafil—Dizziness—Methotrexate—systemic scleroderma	7.3e-05	0.00044	CcSEcCtD
Avanafil—Vomiting—Methotrexate—systemic scleroderma	7.02e-05	0.000423	CcSEcCtD
Avanafil—Rash—Methotrexate—systemic scleroderma	6.96e-05	0.00042	CcSEcCtD
Avanafil—Dermatitis—Methotrexate—systemic scleroderma	6.96e-05	0.000419	CcSEcCtD
Avanafil—Headache—Methotrexate—systemic scleroderma	6.92e-05	0.000417	CcSEcCtD
Avanafil—Nausea—Methotrexate—systemic scleroderma	6.56e-05	0.000395	CcSEcCtD
